---
title: "MIF inhibitor ISO-1 reduces ischemia–reperfusion injury in rat DCD liver transplantation"
id: "plos-one-14-mif-inhibitor-iso-1-attenuates-ischemia-reperfusion-injury-in-a-rat-model-of"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-14-mif-inhibitor-iso-1-attenuates-ischemia-reperfusion-injury-in-a-rat-model-of"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0361214"
published_at: "2026-10-26T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# MIF inhibitor ISO-1 reduces ischemia–reperfusion injury in rat DCD liver transplantation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-14-mif-inhibitor-iso-1-attenuates-ischemia-reperfusion-injury-in-a-rat-model-of
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0361214)
- **Published At:** 2026-10-26T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators used a rat orthotopic liver transplantation model to test whether donor pre-treatment with the **MIF** inhibitor **ISO-1** modulates ischemia–reperfusion injury (IRI) in donation after circulatory death (**DCD**) grafts. - The study randomized 196 male Lewis rats into five groups: DBD control, DCD-30, DCD-60, DCD-30 + ISO-1, and DCD-30 + vehicle, with n = 7 per group per time point for serial sacrifice at 1, 3, 24, and 168 hours post-reperfusion. - **ISO-1** was administered intraperitoneally at 20 mg/kg to donors one hour before cardiac arrest; vehicle contained 5.2% DMSO in saline. - Grafts underwent 3 hours of cold storage in HTK solution at 4°C prior to arterialized orthotopic liver transplantation (**OLT**). - Primary functional readouts included serum transaminases (AST, ALT), LDH, graft microcirculation (O2C device), portal venous flow, histologic Suzuki scoring, CD163+ macrophage infiltration, and serum levels of **HMGB-1** and **MIF** by ELISA. - Data indicated marked injury in DCD grafts, with lethal outcomes in the DCD-60 cohort; **ISO-1** pre-treatment significantly reduced early hepatocellular injury (AST: 294 ± 63 vs 867 ± 211 IU/L, p = 0.017 versus vehicle) and produced values similar to DBD controls. - Serum DAMPs were reduced after **ISO-1**: **HMGB-1** (11 ± 2.8 vs 26 ± 6.2 pg/mL, p = 0.045) and **MIF** (45 ± 5.3 vs 144 ± 27.5 ng/mL, p = 0.034) compared with vehicle. - **ISO-1** was associated with improved graft microcirculation at 24 hours, attenuated histologic injury scores, and altered timing of CD163+ macrophage infiltration. - The authors reported no significant between-group differences in operative variables (anhepatic time, total surgery time, cold ischemia time). - The manuscript provides raw western blot data and notes high mortality in the DCD-60 group with no long-term survival groups for that arm; the source recommends further mechanistic and translational evaluation of **ISO-1** in DCD liver transplantation.
## Clinical Analysis & Structured Key Points
MIF inhibitor ISO-1 attenuates ischemia-reperfusion injury in a rat model of donation after circulatory death liver transplantation | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Macrophage migration inhibitory factor (MIF) is an early mediator of ischemia–reperfusion injury (IRI), however, the evidence on its role in orthotopic liver transplantation (OLT), particularly with donation after circulatory death (DCD) grafts is limited. Given its key regulatory function, this study investigated the effects of IRI on graft injury and assessed whether the use of ISO-1, a small-molecule MIF-inhibitor, affect IRI in a rat DCD-OLT model. 196 male Lewis rats were randomized into DBD control, DCD-30 min, DCD-60 min, DCD-30 + ISO-1, and DCD-30 + vehicle groups (n = 7/group/time-point). ISO-1 was administered before controlled cardiac arrest (0–60 min) and 3 h cold preservation before arterialized OLT. Animals were sacrificed at 1, 3, 24, and 168 h post-reperfusion. DCD grafts showed marked injury, with the DCD-60 group exhibiting lethal IRI. ISO-1 significantly reduced early hepatocellular injury compared with vehicle (AST:294 ± 63 vs 867 ± 211 IU/L, p = 0.017) and resulted in values comparable to DBD controls. Serum HMGB-1 (11 ± 2.8 vs 26 ± 6.2 pg/mL, p = 0.045) and MIF (45 ± 5.3 vs 144 ± 27.5 ng/mL, p = 0.034) levels were similarly decreased following ISO-1 application. ISO-1 improved graft microcirculation at 24 h, attenuated histological injury, and was associated with an altered time course of CD163 + macrophage infiltration. ISO-1 pre-treatment attenuated hepatocellular injury and was associated with improved graft microcirculation and reduced DAMP release, supporting further mechanistic and translational evaluation in DCD liver transplantation. Citation: Uluk D, Liu W, Jiang D, Stoppe C, Meister FA, Kraemer S, et al. (2026) MIF inhibitor ISO-1 attenuates ischemia-reperfusion injury in a rat model of donation after circulatory death liver transplantation. PLoS One 21(10): e0361214. https://doi.org/10.1371/journal.pone.0361214 Editor: Tianwen Wang, Anhui Polytechnic University, CHINA Received: July 11, 2026; Accepted: October 7, 2026; Published: October 26, 2026 Copyright: © 2026 Uluk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: Data are available upon reasonable request addressed to the Institute of Laboratory Animal Science (Pauwelsstrasse 30, 52074 Aachen Tel.: +49 241 80-88606 E-Mail: vtk@ukaachen.de ). All relevant data have been reported in the manuscript and in the supplementary files. Funding: Authors declare that the study was supported by the START-programme of the RWTH Aachen University (#23/19 to ZC & #108/21 to FAM & ZC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. Abbreviations: ALT, alanine aminotransferase; ARRIVE, Animal Research: Reporting of In Vivo Experiments; AST, aspartate aminotransferase; ATP, adenosine triphosphate; DBD, donation after brain death; DCD, donation after circulatory death; DMSO, dimethylsulfoxide; ELISA, enzyme-linked immunosorbent assay; H&E, hematoxylin and eosin; HTK, histidine-tryptophan-α-ketoglutarate; IRI, ischemia reperfusion injury; ISO-1, (S, R)-3-(4-hydroxyphenil)-4,5-dihydro-5-isoxazole acetic acid methyl ester; LDH, lactate dehydrogenase; MIF, macrophage migration inhibitory factor; mRNA, messenger ribonucleic-acid; OLT, orthoptic liver transplantation; PVF, portal venous flow; RT-PCR, Reverse-Transcription Polymerase Chain Reaction; WB, western blotting; WIT, warm ischemia time Introduction Liver transplantation using allografts from donation after circulatory death (DCD) has led to the life-saving and substantial expansion of the donor pool over the past decades [ 1 ]. While offering the potential to increase the number of livers offered for transplantation, ischemia-reperfusion injury (IRI) during DCD organ donation still represents a major risk factor for inferior post-transplant outcomes [ 2 ]. Even though, state of the art organ preservation technology with the use of normothermic regional perfusion and machine perfusion has largely improved the overall donor pool utilization [ 3 , 4 ], allografts from DCD donors besides their short-term risks (such as primary non-function, post-reperfusion syndrome, early allograft dysfunction, graft-related complication), are also often associated with inferior long-term outcomes, due to biliary complications, acute- and chronic rejection, and graft loss [ 5 ]. First described in 1966, macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that functions by inhibiting the random migration of macrophages, thereby retaining them at sites of injury and inflammation [ 6 , 7 ]. MIF is a pleiotropic cytokine which is rapidly released upon stimulation from intra-plasmatic vesicular pools of various cell-types, including immune cells, hepatocytes, endothelial cells [ 8 ]. After activation and secretion, MIF has the ability to promote tissue injury and initiate inflammatory responses on the humoral and cellular level [ 8 ]. The Vienna group has shown for the first time in the clinical setting that human liver grafts release MIF and higher concentrations of MIF are associated with allograft dysfunction and acute kidney injury after OLT [ 8 – 10 ]. Although, our group and others have demonstrated to role of MIF in IRI in various organs [ 8 – 14 ], clinical and experimental scenarios, to the best of our knowledge, no data are available on the modulation of MIF with its inhibitor ISO-1 in the context of IRI and OLT. Therefore, we hypothesized that donor pre-treatment with the MIF inhibitor ISO-1 might attenuate ischemia-reperfusion injury, improve graft function, and modulate the early inflammatory response in a rat model of DCD liver transplantation. Methods Animals and study design This study was designed, conducted and reported based on the ARRIVE (Animal Research: Reporting of In Vivo Experiments) and based on our review article published on reporting standard in experimental studies in rat liver transplantation [ 15 ]. The experiments were approved by Governmental Animal Care and Use Committee (LANUV NRW “Landesamt fuer Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen”, Recklinghausen, Germany, ID: 81–02.04.2017. A 414). All rats in the study received the best possible care according to the principles of the “Guide for the Care and Use of Laboratory Animals” (8th edition, NIH Publication, 2011, USA). Experiments were performed in accordance with the institutional guidelines and the German federal law regarding the protection of animals and the EU Directive 2010/63. Every staff member involved has received all required training according to the local requirements and standards of the Society for Laboratory Animal Science (GV-SOLAS) and Federation of European Laboratory Animal Science Associations (FELASA). All rats were housed in the animal facilities and kept under specific pathogen-free conditions at least 7 days before experiments according to the guidelines of the “Federation for Laboratory Animal Science Associations” (FELASA; www.felasa.eu ) in a temperature- and humidity-controlled environment with a 12/12 day/night cycle. Standard food for laboratory rats (Sniff GmbH, Soest, Germany) and water were granted ad libitum. Confounders were controlled in a way that all personnel involved in the daily care of the animals was blinded for the experimental groups throughout the experiments. Two experiments were conducted in this study: 196 male Lewis rats (LEW/OrlRj; Janvier Labs, Le Genest Saint Isle, France) were divided into 5 groups based on an a priori sample size calculation (alpha = 0.05; 1-beta = 0.8, peak 73% ALT difference between groups based on previous studies of our group) and used to perform 98 arterialized whole-graft isogenic OLTs, (n = 7/group/time point). To comply with the 3R principles, rats in group 1 were also designed as the control group for experiment II to reduce the number of animals used (Reduction principle – 3R). Fig 1 depicts the study protocol. Download: PNG larger image TIFF original image Fig 1. Study flowchart. Animals were randomized into five experimental groups (DBD control group, DCD-30’ group, DCD-60’ group, ISO-1 group, Vehicle group). 60 minutes sham period, 30 minutes sham period + 30 minutes WIT, and 60 minutes WIT were performed in group 1, 2, 4, 5, and 3 before liver retrieval, respectively. Additionally, in group 4 and 5, ISO-1, and DMSO 5% were injected 30 min before laparotomy, respectively. Following liver retrieval, grafts were stored for 3 hours in HTK solution at 4-degree for cold preservation and implanted into the recipient animals. Animals were sacrificed after 1, 3, 24, and 168 hours of reperfusion for sample collection and analysis. Animals in group 1a were also included into the control group for experiment II to reduce the number of animals used. IRI: ischemia reperfusion injury; SCS: static cold storage; HTK: histidine tryptophane ketoglutarate solution; DBD: donation after brain death; DCD: donation after circulatory death; DMSO: dimethylsulfoxide; OLT: orthoptic liver transplantation; WIT: warm ischemia time. https://doi.org/10.1371/journal.pone.0361214.g001 Experiment I. -. Group-1a (DBD control group), before liver retrieval, 60 minutes sham period of anesthesia was performed without further intervention, followed with OLT. -. Group-2 (DCD-30’ group), 30 minutes sham period together with 30 minutes of cardiac arrest was performed before liver retrieval, followed with OLT. Cardiac arrest was achieved in all DCD groups via phrenotomy. -. Group-3 (DCD-60’ group), 60 minutes of cardiac arrest was performed before liver retrieval, followed by OLT. Following 1 hour of “on-table” reperfusion. Animals were sacrificed in deep anesthesia by exsanguination via the vena cava following the assessment of graft perfusion. Sample were collected for further analysis. Due high mortality after 60 min of cardiac arrest and DCD liver transplantation, no long-term survival groups have been established in Experiment I. Experiment II. -. Group-1a + b (DBD control group), similarly, to Experiment I., donor animals of this group underwent 60 minutes of sham period and no further treatment. Recipient animals were sacrificed after 1/3/24/168-hours (n = 7/group/time-point) of graft reperfusion and acted as control group. Data from the 1-hour reperfusion group was used from Experiment I. -. Group-4 (ISO-1 group, DCD-30’ + ISO-1), ISO-1 (Calbiochem, CAS 478336-92-4, San Diego, CA) (20 mg ISO-1 /KG kg) was applied intraperitoneally to the donor animal directly after anesthesia induction (1 hour before cardiac arrest). ISO-1 was diluted with minimal amounts of dimethylsulfoxide (DMSO) (23 mg/mL solution), which was then further diluted with 0.9% NaCl to a final DMSO concentration of 5.2%. Thirty minutes sham period combined with 30 minutes cardiac arrest was performed before liver retrieval, followed by OLT. -. Group-5 (Vehicle group, DCD-30’ + Vehicle) DMSO 5% (DMSO diluted by 0.9% NaCl to a final DMSO concentration of 5.2%) intraperitoneally to the donor animal directly after anesthesia induction (1 hour before cardiac arrest). Thirty minutes sham period combined with 30 minutes cardiac arrest was performed before liver retrieval, followed by OLT. Following the corresponding observation period (1/3/24 or 168 hours) the animals were put into anesthesia and a relaparotomy was carried out to assess graft circulation and collect samples. Animals are sacrificed in deep anesthesia by exsanguination via the vena cava. Liver transplantation All surgeries were performed by the same experienced microsurgeon (Z.C.) and at the same time of day to avoid disturbing effects of circadian rhythm. All rats were anesthetized with 2vol% isoflurane (Forane; Abbott GmbH, Wiesbaden, Germany) and buprenorphine (0.03 mg/kg) (Temgesic; EssexPharma, Haar, Germany) during all the surgical interventions and samples collection. Surgical details of arterialized OLT in rats used in the present study were extensively described by our group earlier [ 16 ]. Briefly, in all donor animals, the liver was perfused via the portal vein with 60 mL of 4˚C Histidine-tryptophan-ketoglutarate (HTK) solution (Custodiol; Dr Franz Koehler Chemie GmbH, Bensheim, Germany) at a hydrostatic pressure of 20 cm H 2 O. Liver was then retrieved en bloc and preserved in HTK solution at 4°C for 3 hours cold preservation and meanwhile, back-table procedures were performed. During recipient surgery, following hepatectomy reconstruction, of the suprahepatic inferior vena cava and portal vein were carried out by end-to-end anastomosis using continuous sutures (Prolene 7–0; Ethicon, Somerville, NJ, USA) and 3.5 mm long 14-gauge polyethylene cuff with circumferential grooves (Vasofix 14G; B. Braun), respectively. Graft was perfused immediately after the portal vein was reconstructed. Infrahepatic inferior vena cava was then reconstructed in the same method as using continuous sutures (Prolene 8–0; Ethicon). For graft re-arterialization and bile duct reconstruction, 24-gauge polyethylene stents (Vasofix 24G; B. Braun) were used in a length of 3.5 mm and 5 mm, respectively. In general, the hepatectomy took around 30 minutes, and the anhepatic time was within 20 minutes. At the end of the surgery, the incision was closed in two layers using continuous 4−0 sutures (Vicryl 4−0; Ethicon). Intraoperative fluid administration was described in detail by our team elsewhere [ 17 ]. Post-operation managements Recipient rats recovered from anesthesia and surgery in a special intensive care unit cage (Vetario; Brinsea Products Ltd, North Somerset, UK) with warmed air (30°C – 35°C) and oxygen supplementation. Antibiotics and analgesia were administered by subcutaneous injection of cefuroxime sodium (16 mg/kg) (Cefuroxim Fresenius; Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany) and buprenorphine (0.03 mg/kg) (Temgesic; EssexPharma, Haar, Germany) every 24 hours until POD 3. Postoperative follow-up and humane endpoint scoring have been performed twice daily as described elsewhere by our working group [ 16 ]. The specific criteria used to determine when animals should be euthanized has been attached as online supplement ( S2_Score_Sheet ). Serum transaminases and graft circulation Blood samples from the inferior vena cava, were centrifuged (4°C, 10 minutes, 2,500 rpm) and then levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) were measured using standard photometric procedures in an automated analyzer (Vitros 250; Johnson and Johnson, Neuss, Germany). Serum transaminases have been expressed as IU/L. Graft microcirculation and portal venous flow were measured using an O2C device (O2C-oxygen to see device, LF1 surface probe; LEA Medizintechnik GmbH, Giessen, Germany) and transit-time perivascular flowmeter (T403 device, MA2PSB flow probe; Transonic Systems, Inc., Ithaca, NY, USA), respectively. Details of measurement have been described elsewhere by our working group [ 16 ]. Histology and immunohistochemistry Liver samples were harvested from mediate lobe for histopathology. First, the excised tissue was fixed in 10% neutral buffered formalin. Second, 4 mm to 6 mm thick Slides embedded by paraffin were stained with H&E (hematoxylin and eosin). All slides were evaluated using a semiquantitative scoring system adopted from Suzuki et al. by an experienced veterinary pathologist in a blinded fashion, assessing congestion, vacuolization, and hepatocyte necrosis [ 16 ]. To simplify the results, a total score was generated (none = 0; minimal = 1; mild –30% = 2; moderate 30–60% = 3; severe >60% = 4). Immunohistochemical double-staining of FFPE liver tissue sections was carried out using rat recombinant anti-CD163 monoclonal antibodies (Abcam, Cambridge, UK, EPR19518, ab289979). Ten randomly chosen, nonoverlapping fields (400x magnification) were scored using light microscopy (Leica DM 2500; Leica Microsystems GmbH, Wetzlar, Germany). mRNA expression by reverse-transcription polymerase chain reaction (RT-PCR) To measure the messenger ribonucleic-acid (mRNA) expression in the liver tissue, RT-PCR was performed using TaqMan technology. Specific TaqMan probes (Thermo Fisher Scientific, Waltham, MA, USA, 4331182, Rn00821234_g1) were used on a StepOne Plus Cycler (Applied Biosystems). Methods in detail were described elsewhere by our study group [ 18 ]. Protein expression by western blot (WB) Protein expression in liver tissue was detected using WB technique (DC-Protein Assay Kit, BIO-RAD Laboratories, Munich, Germany) as described previously by our group [ 16 ]. Incubation with specific antibodies against MIF (Cell Signaling Technology, Danvers MA, USA) was performed. The results were displayed as integrated density value (IDV), relative to GAPDH (Glyceraldehyde 3-phosphate dehydrogenase). Western blot images have been grouped only for better visualization, raw data have been provided as online supplement (Supplementary Data 1) HMGB-1 and MIF enzyme-linked immunosorbent assay (ELISA) Serum HMGB-1 and MIF levels were assessed using commercially available rat HMGB-1 and MIF ELISA kits (ST51011, IBL Int GmbH, Hamburg, Germany; CSB-E07293r, Cusabio Technology LLC, Houston,Tex, USA) according to the manufacturer’s instructions. Statistical analysis Two-way analysis of variance (ANOVA) and Bonferroni post hoc correction were performed to analyze changes in time-dependent parameters and between-group differences in each timepoint. Non-parametric Kruskal–Wallis H test was used to test the differences between three groups. A p -value < 0.05 was considered as significance, and adjusted P-value was applied when data have been corrected with multiple comparisons. All statistical analyses were calculated and plotted by GraphPad Prism 10 (GraphPad Software Inc, San Diego, Calif., USA). Results General characteristics of experimental animals and surgical quality indicators, anhepatic time (p = 0.08 between groups, Kruskal–Wallis H test), total surgery time (p = 0.08), cold ischemia time (p = 0.12) did not differ significantly between control and experimental groups as illustrated in Table 1 . Download: PNG larger image TIFF original image Table 1. General characteristics of the experimental animals and intra-operative parameters for quality assurance. https://doi.org/10.1371/journal.pone.0361214.t001 Experiment I – Graft injury in DCD liver transplantation using livers subjected to various degrees of IRI To characterize different degrees of graft injury in our model following DBD, DCD with 30- or 60-minutes cardiac arrest, we monitored serum AST, ALT, and LDH levels and assessed graft macro- and microcirculation at sacrifice in each recipient ( Fig 2 ). Download: PNG larger image TIFF original image Fig 2. Serum markers of hepatocellular injury (A-C) and graft macro- and microcirculation (D-F) following OLT subjected to various degrees of IRI. *p < 0.05, ***p < 0.001; values are expressed as median & interquartile range; n = 7/group/time point. Abbreviations used: AST-Aspartate aminotransferase; ALT-Alanine aminotransferase; LDH-Lactate dehydrogenase; AU-Artificial unit. https://doi.org/10.1371/journal.pone.0361214.g002 While animals of the DBD group only showed a mild increase in serum transaminases (AST: 224 ± 20 IU/L / ALT
## Related Clinical Research

- [Clinical features and hospital management of snakebite in Northern Uganda: multi-facility review](https://medichelpline.com/clinical-feed/plos-one-15-clinical-features-first-aid-practices-and-hospital-management-of-snakebites-in.md)
- [Ransomware in US Health Care: Faster Exploitation and Smaller Breaches, 2016–2026](https://medichelpline.com/clinical-feed/medrxiv-6-the-shrinking-grace-period-and-the-downsizing-of-ransomware-victims.md)
- [Fentanyl dabbing with cannabis retail equipment: prevalence, practices, and clinical signals](https://medichelpline.com/clinical-feed/medrxiv-8-fentanyl-dabbing-with-cannabis-retail-equipment-an-ethnographic-and-drug.md)
- [Admission interleukin-6 and short-term prognosis in hospitalized cirrhosis: etiology-dependent, ti](https://medichelpline.com/clinical-feed/plos-one-19-admission-interleukin-6-as-a-time-limited-etiology-dependent-prognostic-signal.md)
- [Renal Consequences of Inhaled Nitric Oxide in Critically Ill Patients](https://medichelpline.com/clinical-feed/pubmed-43061996.md) (DOI: 10.4103/mgr.MEDGASRES-D-26-00116)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.